{"entity":{"id":"nct06441344","kind":"trial","name":"Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell","aka":["SCLC"],"tldr":"A phase 3 trial of toripalimab and anlotinib in lung cancer, run by Taizhou Hospital, not yet recruiting.","summary":"Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell is a phase 3, randomised interventional study registered as NCT06441344 by Taizhou Hospital, with a registry enrolment figure of 136 participants, started 2024-07-01 and due to reach its primary completion in 2026-05-01. Interventions recorded: Toripalimab plus Anlotinib; Toripalimab. Conditions listed: SCLC; Maintenance Treatment. Primary outcome: progression free survival(PFS); overal survival time(OS). Lung eligibility wording from the registry: \"* Confirmed as small cell lung cancer (SCLC) by histopathology or cytology and diagnosed as extensive after systemic evaluation\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06441344","url":"https://clinicaltrials.gov/study/NCT06441344"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["extensive-stage-sclc"],"sections":[],"technologies":["antiangiogenic","checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":["toripalimab","anlotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06441344","phase":"3","setting":"First-line Etoposide Combined With Platinum-based Chemotherapy Followed by Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell Carcinoma - A Randomized, Controlled, Multicenter Phase III Clinical Study","sponsor":"Taizhou Hospital","enrolled":136,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06441344/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}